Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 150 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 150 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - sodium ascorbate, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: water for injections - sodium ascorbate solution injection for intravenous infusion is indicated for the treatment of vitamin c deficiency when oral treatment is not feasible.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid - indications as at 9 october 2002: sodium chloride (0.9%) intravenous infusion is indicated for extracellular fluid replacement and in the management of metabolic alkalosis in the presence of fluid loss, and for restoring or maintaining the concentration of sodium and chloride ions.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium acetate, quantity: 3.68 g/l; potassium chloride, quantity: 370 mg/l; magnesium chloride hexahydrate, quantity: 300 mg/l; sodium gluconate, quantity: 5.02 g/l; sodium chloride, quantity: 5.26 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium gluconate, quantity: 5.02 g/l; sodium acetate, quantity: 3.68 g/l; sodium chloride, quantity: 5.26 g/l; magnesium chloride hexahydrate, quantity: 300 mg/l; potassium chloride, quantity: 370 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid; sodium chloride - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.